Epirus Switzerland, a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, and Ranbaxy Laboratories, a division of Daiichi Sankyo, Tokyo, have signed a licensing agreement for BOW015, a biosimilar infliximab, for territories including India, selected South East Asian markets and North Africa.
Epirus and Ranbaxy will initially pursue the commercialization of BOW015, the Epirus biosimilar molecule to REMICADE, in India. Epirus recently announced successful phase III data for BOW015 and, in November, filed for market approval. Subsequent to launch in India, Ranbaxy will pursue registration and commercialization of BOW015 in other territories in South East Asia, North Africa and selected other markets.
In exchange for the rights to BOW015 in the territories, Epirus will receive upfront, milestone and royalty payments.